Follow-up of NMO patient sera analyzed using a commercially available NMO-IgG kit and the HSS-CBA test.

Note the difference between NMO-IgG evaluated using the test on monkey cerebellum or the HSS-CBA test. 9/15 samples were negative with the cerebellum-based test, while all the samples were positive on cells. Note the good correlation between the cell based test and Cascade Plasma Filtration therapy (CPFT) treatment. Serum titer was measured by limiting dilution.
*Yes: exacerbation phase of the disease; No: inactivity phase of the disease.
**Samples 7–14 were collected during a 15 day cycle of CPFT (one therapeutic session every other day) planned because of a severe exacerbation. Serum samples were collected before and after each CPFT session.